Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.

[1]  J. Dunst,et al.  Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. , 2002, International journal of radiation oncology, biology, physics.

[2]  C. Sternberg.  Current perspectives in muscle invasive bladder cancer. , 2002, European journal of cancer.

[3]  H. Maase.  Current and future perspectives in advanced bladder cancer: is there a new standard? , 2002 .

[4]  J. Southgate,et al.  Role of p53 in the responses of human urothelial cells to genotoxic damage , 2001, International journal of cancer.

[5]  A. Hart,et al.  Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. , 2001, International journal of radiation oncology, biology, physics.

[6]  G. Peters,et al.  End-joining deficiency and radiosensitization induced by gemcitabine. , 2001, Cancer research.

[7]  S. McKeown,et al.  Induction and Rejoining of DNA Double-Strand Breaks in Bladder Tumor Cells , 2000, Radiation research.

[8]  M. Gulisano,et al.  Effects of Gemcitabine in Normaland Transformed Human Lung Cell Cultures: Cytotoxicity and Increase in Radiation Sensitivity , 1999, Tumori.

[9]  C. Mcginn,et al.  Radiosensitization by gemcitabine. , 1999, Oncology.

[10]  J. Tepper,et al.  Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Böttcher,et al.  [The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine]. , 1999, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[12]  N. Curtin,et al.  Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. , 1998, British Journal of Cancer.

[13]  T. Lawrence,et al.  Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  R. Grenman,et al.  p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines , 1996, Cell proliferation.

[15]  H. Böttcher,et al.  Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. , 2000, Anticancer research.

[16]  T. Lawrence,et al.  The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization , 2000, Cancer Chemotherapy and Pharmacology.

[17]  V. Grégoire,et al.  The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. , 1999, International journal of radiation biology.